Loading data for MKGAF — first visit, this takes a few seconds.
Merck KGaA
157.36 +3.15 (2.04%)
- Market Cap
- $65.36B
- Volume
- 660
- Dividend yield
- 1.64%
- Next earnings date
- Nov 12, 2026
Merck KGaA (MKGAF) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | — | n/a | n/a |
| EPS | — | n/a | n/a |
Metrics
- Bid
- 148.9
- Market Cap
- 65.4B
- Revenue (ttm)
- 21.1B
- Net Income (ttm)
- 2.37B
- 0.81
- 6.3
- 23.86
- n/a
- P/B (ttm)
- 1.87
- P/S (ttm)
- 3.09
- Earnings Date
- Nov 12, 2026
- Ask
- 158.33
- Volume
- 660
- Avg. Volume (20D)
- 506
- Open
- 155.00
- Previous Close
- 154.21
- Day's Range
- 155.00 - 155.00
- 52-Week Range
- 116.68 - 175.56
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- $2.58 (1.64%)
- Ex-Dividend Date
- Apr 27, 2026
About Merck KGaA
View profile →Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
Sector Healthcare
IPO Date Aug 3, 2012
Employees 62,136
Stock Exchange OTC Markets OTCPK
Ticker Symbol MKGAF
Website https://www.emdgroup.com